Stephan Maus

225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience

Fadi Khreish, Niklas Ebert, Martin Ries et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2019 · 213 citations

Medicine, Oncology, Pharmacology +16

DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy

Jörg Fahrer, Stephan Maus, Frank Bruchertseifer et al. · PLoS ONE · 2014 · 137 citations · Full text

Medicine, Oncology, Pharmacology +17

177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study)

Fadi Khreish, Zaidoon Ghazal, Robert J. Marlowe et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2021 · 89 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Molecular imaging and biochemical response assessment after a single cycle of [²²⁵Ac]Ac-PSMA-617/[¹⁷⁷Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [¹⁷⁷Lu]Lu-PSMA-617 monotherapy

Florian Rosar, Fabian Hau, Mark Bartholomä et al. · Theranostics · 2021 · 82 citations · Full text

Medicine, Nuclear Medicine, Oncology +17

Efficacy and Safety of [225Ac]Ac-PSMA-617 Augmented [177Lu]Lu-PSMA-617 Radioligand Therapy in Patients with Highly Advanced mCRPC with Poor Prognosis

Florian Rosar, Jonas Krause, Mark Bartholomä et al. · Pharmaceutics · 2021 · 59 citations · Full text

Medicine, Nuclear Medicine, Oncology +17